KR910016770A - 글리코사미노글리칸-변형된 단백질 - Google Patents

글리코사미노글리칸-변형된 단백질 Download PDF

Info

Publication number
KR910016770A
KR910016770A KR1019900016160A KR900016160A KR910016770A KR 910016770 A KR910016770 A KR 910016770A KR 1019900016160 A KR1019900016160 A KR 1019900016160A KR 900016160 A KR900016160 A KR 900016160A KR 910016770 A KR910016770 A KR 910016770A
Authority
KR
South Korea
Prior art keywords
glycosaminoglycan
protein
modified protein
residue
excluding
Prior art date
Application number
KR1019900016160A
Other languages
English (en)
Other versions
KR100188382B1 (ko
Inventor
가츄키요 사쿠라이
키요슈제 미야자키
Original Assignee
야마디니 와다루
세이카가쿠고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 야마디니 와다루, 세이카가쿠고교 가부시키가이샤 filed Critical 야마디니 와다루
Publication of KR910016770A publication Critical patent/KR910016770A/ko
Application granted granted Critical
Publication of KR100188382B1 publication Critical patent/KR100188382B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

내용 없음

Description

글리코사미노글리칸-변형된 단백질
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도 내지 3도는 실시예에서 수득된 글리코 사미노글리칸-변형된 단백질 및 글리코사미노글리칸과 단백질의 혼합물의 전기영동 패턴을 나타낸다.

Claims (9)

  1. 글리코사미노글리칸의 환원성 말단 당 잔기를 환원시키고 부분적으로 산화시켜 형성된 알데하이드 그룹에 단백질의 아미노 그룹이 결합된 글리코사미노글리칸-변형된 단백질.
  2. 일반식(Ⅰ)의 글리코사미노글리칸-변형된 단백질.
    상기식에서, P는 단백질로부터 n개의 아미노 그룹을 제외한 단백질 잔기이고, n은 1 내지 100의 정수이며, GAG는 글리코사미노글리칸의 환원성 말단 당 잔기를 제외한 글리코사미노글리칸이다.
  3. 일반식(Ⅱ)의 글리코사미노글리칸-변형된 단백질.
    상기식에서, P는 단백질로부터 n개의 아미노 그룹을 제외한 단백질 잔기이고, n은 1 내지 100의 정수이며, GAG는 글리코사미노글리칸으로부터 환원성 말단 당 잔기를 제외한 글리코사미노글리칸이다.
  4. 일반식(Ⅲ)의 글리코사미노글리칸-변형된 단백질.
    상기식에서, P는 단백질로부터 n개의 아미노 그룹을 제외한 단백질 잔기이고, n은 1 내지 100의 정수이며, GAG는 글리코사미노글리칸으로부터 환원성 말단 당 잔기를 제외한 글리코사미노글리칸이다.
  5. 글리코사미노글리칸의 우론산 잔기에 최소한 몇몇 카복실 그룹이 아미드 결합을 통하여 단백질에 결합된 글리코사미노글리칸-변형된 단백질.
  6. 제1항에 있어서, 글리코사미노글리칸 함량이, 단백질의 중량을 기준으로 하여, 1 내지 99.9중량%의 범위인 글리코사미노글리칸-변형된 단백질.
  7. 제1항에 있어서, 글리코사미노글리칸이 콜로민산, 히알우론산, 콘드로이틴, 콘드로이틴 설페이트, 테이추론산, 더마탄 설페이트, 헤파린, 헤파린 설페이트, 케라토설페이트, 케라토폴리설페이트 및 이의 유도체들 중에서 선택되는 글리코사미노글리칸-변형된 단백질.
  8. 글리코사미노글리칸을 환원성 말단 잔기-제한적 산화 방법, 카복실 그룹-활성화 법, 환원성 말단 잔기-락톤화 방법 또는 시아노겐 브로마이드 활성화 방법에 의해 활성화시킨 후, 활성화된 글리코사미노글리칸을 단백질과 반응시킴으로 특징으로 하는 제1항에 따른 글리코사미노글리칸-변형된 단백질의 제조방법.
  9. 제1항에 따른 글리코사미노글리칸-변형된 단백질 및 약제학적으로 허용되는 담체 또는 희석제를 함유하는 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900016160A 1990-03-30 1990-10-12 글리코사미노글리칸 변형된 단백질 및 이를 포함하는 약제학적 조성물 _ KR100188382B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2081163A JP2975632B2 (ja) 1990-03-30 1990-03-30 グリコサミノグリカン修飾プロテイン
JP2-81163 1990-03-30

Publications (2)

Publication Number Publication Date
KR910016770A true KR910016770A (ko) 1991-11-05
KR100188382B1 KR100188382B1 (ko) 1999-06-01

Family

ID=13738789

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900016160A KR100188382B1 (ko) 1990-03-30 1990-10-12 글리코사미노글리칸 변형된 단백질 및 이를 포함하는 약제학적 조성물 _

Country Status (12)

Country Link
US (1) US5310881A (ko)
EP (1) EP0454898B1 (ko)
JP (1) JP2975632B2 (ko)
KR (1) KR100188382B1 (ko)
AT (1) ATE135375T1 (ko)
AU (1) AU649416B2 (ko)
CA (1) CA2027447A1 (ko)
DE (1) DE69025920T2 (ko)
DK (1) DK0454898T3 (ko)
ES (1) ES2083989T3 (ko)
FI (1) FI102836B (ko)
NO (1) NO179044C (ko)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0502550B1 (en) * 1991-03-07 1995-01-04 Mect Corporation Colominic acid and partial hydrolysis products of colominic acid for the preparation of medicaments for the treatment of hepatitis, nephritis and arthritis
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
GB9112212D0 (en) * 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
GB2266239B (en) * 1992-03-25 1996-03-06 Jevco Ltd Wound healing compositions containing chondroitin sulphate oligosaccharides
CA2091544A1 (en) * 1992-03-26 1993-09-27 Shing F. Kwan Stabilization of functional proteins
EP0744409B9 (en) * 1994-02-23 2009-08-19 Kyowa Hakko Kogyo Co., Ltd Platelet growth accelerator
JPH09503001A (ja) * 1994-05-09 1997-03-25 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング ニューロンを保護するためのコンドロイチン硫酸プロテオグリカンの使用
US6228998B1 (en) 1994-07-22 2001-05-08 Seikagaku Kogyo Kabushiki Kaisha Amino spacered glycosaminoglycan derivatives and their use in copolymerization with acrylamide
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
WO1996009805A2 (en) * 1994-09-23 1996-04-04 Zonagen, Inc. Chitosan induced immunopotentiation
US5677276A (en) * 1994-12-23 1997-10-14 La Jolla Cancer Research Foundation Immobilization of peptides to hyaluronate
RU2176509C2 (ru) * 1995-09-19 2001-12-10 Сейкагаку Корпорейшн Средство, усиливающее противовоспалительное действие иммунодепрессанта (варианты), способ усиления противовоспалительного действия иммунодепрессанта, способ лечения воспаления
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6491965B1 (en) 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
CA2266747A1 (en) * 1996-09-25 1998-04-02 Mary Ann Childs Diagnostic test devices with improved fluid movement and resistance to interferences
WO2001005434A2 (en) * 1999-07-20 2001-01-25 Amgen Inc. Hyaluronic acid-protein conjugates
EP2298354B1 (en) * 2001-10-10 2014-03-19 ratiopharm GmbH Remodelling and glycoconjugation of interferon-beta
EP2292271A3 (en) * 2001-10-10 2011-09-14 BioGeneriX AG Remodelling and glycoconjugation of an antibody
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
WO2004024776A1 (en) 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
US7862831B2 (en) * 2002-10-09 2011-01-04 Synthasome, Inc. Method and material for enhanced tissue-biomaterial integration
EP1558216A4 (en) * 2002-09-25 2007-01-03 Univ Johns Hopkins Med RETICULATED POLYMER MATRICES AND METHOD OF MANUFACTURING THE SAME
US8673333B2 (en) * 2002-09-25 2014-03-18 The Johns Hopkins University Cross-linked polymer matrices, and methods of making and using same
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US7807824B2 (en) 2003-08-12 2010-10-05 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
WO2006089119A2 (en) * 2005-02-18 2006-08-24 Cartilix, Inc. Biological adhesive
WO2006090119A1 (en) 2005-02-23 2006-08-31 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
WO2012170504A2 (en) * 2011-06-06 2012-12-13 The Cleveland Clinic Foundation Treatment of extracellular matrix to reduce inflammation
WO2015046602A1 (ja) 2013-09-30 2015-04-02 生化学工業株式会社 タンパク質の血中滞留性の増強方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2824092A (en) * 1955-01-04 1958-02-18 Robert E Thompson Process of preparation of a gelatincarboxymethyl cellulose complex
GB1479268A (en) * 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4301153A (en) * 1977-03-21 1981-11-17 Riker Laboratories, Inc. Heparin preparation
CA1171375A (en) * 1980-09-15 1984-07-24 Ulf P.F. Lindahl Oligosaccharides having selective anticoagulation activity
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4526714A (en) * 1982-12-13 1985-07-02 Cordis Europa N.V. Conjugates of anticoagulant and protein
NL188622C (nl) * 1981-12-15 1992-08-17 Cordis Europ Werkwijze ter verbetering van de bloedcompatibiliteit van een materiaaloppervlak door bekleding daarvan met een heparine of heparine-analoga en een eiwit houdende film, alsmede voorwerp, omvattende een oppervlak met verbeterde bloedcompatibiliteit verkregen onder toepassing van een op het oppervlak aangebrachte heparine of heparine-analoga en een eiwit houdende film.
SE8200751L (sv) * 1982-02-09 1983-08-10 Olle Larm Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter
US4585754A (en) * 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
US4863907A (en) * 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use
DE3680524D1 (de) * 1986-04-22 1991-08-29 Valcor Scient Ltd Verfahren zur stabilisierung von proteinen.
US4745180A (en) * 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
DE3636590A1 (de) * 1986-10-28 1988-05-26 Braun Melsungen Ag Blutersatzmittel
FR2631970B1 (fr) * 1988-05-24 1993-12-24 Sanofi N-polyosyl-polypeptides
DE3819079A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Hirudin-derivate mit verzoegerter wirkung
WO1990001332A1 (en) * 1988-08-10 1990-02-22 Cetus Corporation Plasminogen activator-heparin conjugates

Also Published As

Publication number Publication date
ES2083989T3 (es) 1996-05-01
FI905003A (fi) 1991-10-01
DE69025920T2 (de) 1996-08-14
ATE135375T1 (de) 1996-03-15
EP0454898A1 (en) 1991-11-06
FI102836B1 (fi) 1999-02-26
NO179044C (no) 1996-07-24
DE69025920D1 (de) 1996-04-18
NO904378D0 (no) 1990-10-10
FI102836B (fi) 1999-02-26
JPH03284698A (ja) 1991-12-16
US5310881A (en) 1994-05-10
NO179044B (no) 1996-04-15
CA2027447A1 (en) 1991-10-01
DK0454898T3 (da) 1996-04-15
KR100188382B1 (ko) 1999-06-01
NO904378L (no) 1991-10-01
AU6450690A (en) 1991-10-31
AU649416B2 (en) 1994-05-26
EP0454898B1 (en) 1996-03-13
FI905003A0 (fi) 1990-10-11
JP2975632B2 (ja) 1999-11-10

Similar Documents

Publication Publication Date Title
KR910016770A (ko) 글리코사미노글리칸-변형된 단백질
ATE131176T1 (de) Sulfatierte polysaccharide, antikoagulierungs- und antikomplementärmittel, hergestellt aus fukanen aus braunen algen, und verfahren zu deren herstellung.
KR920009389A (ko) 외용 피부학적 조성물
DK0527821T3 (da) Oxidationsresistente thrombomodulinanaloger
KR830007567A (ko) 1, 2, 3, 4-테트라하이드로이소퀴놀린-3-카복실산의 치환아실 유도체의 제조방법.
DE68921633D1 (de) Oligosaccharide mit antiatherosclerotischer wirkung.
KR840009031A (ko) 니모디핀-함유 제제의 제조방법
KR880013534A (ko) 콘 돔
KR900003163A (ko) 시클로헥산 유도체
KR890016922A (ko) 복합 감미료
ATE68813T1 (de) Klebstoffderivate von bioadhaesiven polyphenolproteinen.
EP1548004A1 (en) Biological low-molecular weight derivatives
KR910016767A (ko) 신규한 펩티드
KR890014448A (ko) 아실페놀 유도체
ATE92965T1 (de) Familie von auf xanthan basierenden polysaccharidpolymeren, welche sowohl nichtacetylierten und/oder nichtpyruvylierten gummi als auch acetylierten oder nichtacetylierten polytetramer-gummi beeinhalten.
EA199800778A1 (ru) Способ окисления полисахарида
ATE150468T1 (de) Dermatansulfatoligosaccharide, verfahren zu ihrer herstellung und diese enthaltende phamazeutische zusammensetzungen
ATE168115T1 (de) In lösung bringen von proteinen in aktiver form
ES2068527T3 (es) Compuesto polisacaridico deslipidado, procedimiento de preparacion, composiciones que lo comprenden.
ATE6148T1 (de) Hexapeptide, deren herstellung, deren anwendung in arzneimitteln und sie enthaltende zusammensetzungen.
KR890009386A (ko) 백금화합물 동결건조제제
KR920019363A (ko) 폴리아데닐산과 폴리우리딜산과의 복합물
KR920009788A (ko) 수용성 이산화티오요소 유도체 및 그의 제조방법
KR870007115A (ko) 피로글루타미드 유도체
KR920000823A (ko) 폴리 아미드 탄성체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee